Insider Selling: DexCom, Inc. (NASDAQ:DXCM) COO Sells $990,668.88 in Stock

DexCom, Inc. (NASDAQ:DXCM) COO Jacob Steven Leach sold 14,076 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the sale, the chief operating officer now owns 313,497 shares in the company, valued at $22,063,918.86. The trade was a 4.30 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Jacob Steven Leach also recently made the following trade(s):

• On Wednesday, January 29th, Jacob Steven Leach sold 2,634 shares of DexCom stock. The shares were sold at an average price of $86.91, for a total value of $228,920.94.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $70.69 on Monday. The stock has a fifty day moving average price of $83.99 and a two-hundred day moving average price of $76.93. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a market cap of $27.62 billion, a P/E ratio of 49.43, a PEG ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on DXCM shares. Morgan Stanley upped their price objective on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Canaccord Genuity Group increased their price target on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Finally, Citigroup increased their price target on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $99.82.

Hedge Funds Weigh In On DexCom

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DXCM. Covestor Ltd boosted its stake in shares of DexCom by 53.7% during the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after acquiring an additional 335 shares in the last quarter. Crossmark Global Holdings Inc. boosted its stake in shares of DexCom by 1.0% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock worth $1,259,000 after acquiring an additional 182 shares in the last quarter. Harbour Investments Inc. boosted its stake in shares of DexCom by 8.8% during the 3rd quarter. Harbour Investments Inc. now owns 12,895 shares of the medical device company’s stock worth $864,000 after acquiring an additional 1,046 shares in the last quarter. GSA Capital Partners LLP boosted its stake in shares of DexCom by 129.1% during the 3rd quarter. GSA Capital Partners LLP now owns 10,268 shares of the medical device company’s stock worth $688,000 after acquiring an additional 5,787 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd bought a new stake in shares of DexCom during the 3rd quarter worth $221,000. 97.75% of the stock is owned by institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.